Literature DB >> 17983855

Appetite and metabolic effects of ghrelin and cannabinoids: involvement of AMP-activated protein kinase.

Hinke van Thuijl1, Blerina Kola, Márta Korbonits.   

Abstract

Obesity is one of the most important health threats to the Western world, and the physiology of appetite-regulating hormones has become a major interest in the last decades. One of the orexigenic hormones, ghrelin is the stomach-derived "brain-gut" peptide, which stimulates energy consumption and storage. Ghrelin promotes gluconeogenesis and adipose tissue deposition. Endocannabinoids, such as anandamide and 2-arachydoglycerol, are lipid-like neurotransmitter molecules activating the cannabinoid receptors. Endocannabinoids, apart from the well-known psychological effects, cause an increase in appetite, and they peripherally promote de novo fatty acid synthesis and gluconeogenesis. Adenosine monophosphate-activated protein kinase (AMPK) is an energy-sensing kinase, which responds to changes in the energy levels of the cell and the whole body in order to maintain adequate ATP levels in the cell. Recently, several hormones have been shown to regulate AMPK activity, and interestingly in a strictly tissue-specific manner. Orexigenic agents such as ghrelin and cannabinoids stimulate hypothalamic AMPK leading to increase in appetite while inhibiting AMPK activity in the liver and adipose tissue, therefore leading to lipogenic and diabetogenic effects. Here we summarize the recent data on hormonal AMPK regulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17983855     DOI: 10.1016/S0083-6729(06)77006-6

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  9 in total

Review 1.  Adipose-immune interactions during obesity and caloric restriction: reciprocal mechanisms regulating immunity and health span.

Authors:  Vishwa Deep Dixit
Journal:  J Leukoc Biol       Date:  2008-06-25       Impact factor: 4.962

Review 2.  Ghrelin forms in the modulation of energy balance and metabolism.

Authors:  Gianluca Gortan Cappellari; Rocco Barazzoni
Journal:  Eat Weight Disord       Date:  2018-10-24       Impact factor: 4.652

3.  Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine.

Authors:  Hyunjeong Kim; Minsun Park; Su-Kyoung Lee; Jihyeon Jeong; Kee Namkoong; Hyun-Sang Cho; Jin Young Park; Byung-In Lee; Eosu Kim
Journal:  Psychopharmacology (Berl)       Date:  2014-04-15       Impact factor: 4.530

4.  Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities.

Authors:  Pedro Cunha; Ana M Romão; Filipa Mascarenhas-Melo; Helena M Teixeira; Flávio Reis
Journal:  J Pharm Bioallied Sci       Date:  2011-07

Review 5.  Structure and physiological actions of ghrelin.

Authors:  Christine Delporte
Journal:  Scientifica (Cairo)       Date:  2013-11-28

6.  Resistin-like molecule-beta inhibits SGLT-1 activity and enhances GLUT2-dependent jejunal glucose transport.

Authors:  Rim Belharbi Krimi; Philippe Letteron; Pia Chedid; Corinne Nazaret; Robert Ducroc; Jean-Claude Marie
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

7.  Effect of ghrelin on aldolase gene expression in the heart of chronic hypoxic rat.

Authors:  Mohammad Reza Aliparasti; Mohammad Reza Alipour; Shohreh Almasi; Hadi Feizi
Journal:  Int J Endocrinol Metab       Date:  2012-06-30

8.  Ghrelin-induced orexigenic effect in rats depends on the metabolic status and is counteracted by peripheral CB1 receptor antagonism.

Authors:  Francisco Alen; Inmaculada Crespo; María Teresa Ramírez-López; Nadine Jagerovic; Pilar Goya; Fernando Rodríguez de Fonseca; Raquel Gómez de Heras; Laura Orio
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

9.  The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake.

Authors:  Lucia L Senin; Omar Al-Massadi; Cintia Folgueira; Cecilia Castelao; Maria Pardo; Silvia Barja-Fernandez; Arturo Roca-Rivada; Maria Amil; Ana B Crujeiras; Tomas Garcia-Caballero; Enrico Gabellieri; Rosaura Leis; Carlos Dieguez; Uberto Pagotto; Felipe F Casanueva; Luisa M Seoane
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.